BiotechTube

Kuvan®

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria

Trial Timeline

Oct 1, 2013 → Jan 4, 2023

NCT ID
NCT01965912

About Kuvan®

Kuvan® is a approved stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT01965912. Target conditions include Phenylketonuria.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT01965912ApprovedCompleted
NCT01376908Phase 3Completed
NCT00943579Phase 2/3Completed

Competing Products

20 competing products in Phenylketonuria

See all competitors
ProductCompanyStageHype Score
SYNB1934v1 + PlaceboSynlogicPhase 3
69
SYNB1618 + PlaceboSynlogicPhase 1/2
33
SYNB1618 + SYNB1934SynlogicPhase 2
44
Kuvan®MerckPhase 3
77
Kuvan®MerckApproved
85
SAR444836SanofiPhase 1/2
40
KuvanBioMarin PharmaceuticalPre-clinical
20
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
20
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
49
BMN 307BioMarin PharmaceuticalPhase 1/2
38
SapropterinBioMarin PharmaceuticalPre-clinical
20
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
74
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
74
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
74
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
82
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
PegvaliaseBioMarin PharmaceuticalPre-clinical
20

Other Products from BioMarin Pharmaceutical

NaglazymeApproved
82
saproterin dihydrochlorideApproved
82
Pegvaliase + MethotrexateApproved
82
KuvanApproved
82
BH4Approved
82